News & events
| News
Fewer adverse events reported following NIP pneumococcal vaccine change
| News
New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations
| News
2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination
| News
AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines
| News
New JN.1 COVID-19 vaccines well tolerated, AusVaxSafety data show
| News
AusVaxSafety publishes Australian-first safety data for Arexvy RSV vaccine
| News
New report re-affirms short-term safety of vaccines in Australia
| News
Enhanced National Immunisation Program vaccine safety data now available
| News
AusVaxSafety study affirms short-term safety profile of Moderna and Novavax COVID-19 vaccine priming doses
| News
AusVaxSafety marks a decade of progress in vaccine safety
All news & events
| News

New JN.1 COVID-19 vaccines well tolerated, AusVaxSafety data show

Active AusVaxSafety surveillance data monitoring the safety of Pfizer JN.1 COVID-19 vaccine (aged 12 years and over formulation) show that most participants (73%) experienced no side effects in the first three days following vaccination.  

To date, AusVaxSafety has received data from more than 11,500 Pfizer JN.1 COVID-19 vaccine recipients who participated in active vaccine safety surveillance via the AusVaxSafety monitoring system.

Among the side effects experienced, local reaction (including pain, itching, redness and swelling at the injection site), fatigue, muscle/joint pain and headache were most common.

These side effects were generally mild and short-lived, with most resolving within one day or less. Their impact on routine activities was low, with just 4% of Pfizer JN.1 respondents reporting missing work, study or routine duties in the week following vaccination.

Reported medical attendance rates also remained low, at less than 0.2%.

These new safety data have been released as part of the ongoing AusVaxSafety COVID-19 vaccine surveillance program and are updated monthly.
 

View the latest JN.1 COVID-19 vaccine safety data